My feeling is, that if Purdue is behind the manipulation, then they are concerned that success by Ipci will be detrimental to their market position on opiods. That would explain the determined effort by them or their agents to get the company delisted. If Ipci doesn't protect their interests then that may be the inevitable outcome. This is without even considering what a deep pocket competitor could do to exert undue influence on the FDA. All of these possibilities, unfortunately, have occurred before to other companies. Let's hope the company has a viable strategy going forward to rebuff these attacks on its stock price and on its reputation. We have to hope for the best. Best of luck to all, we're going to need it.
News 
Market Data 
Discover 
